Delivery Order SPE2DB20D3303-SPE2DB24FA3HP

Award Date 9/20/24
Potential Completion Date 9/23/24
Potential Value $4.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $2,494.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of INSULIN GLARGINE-YFGN U100 PEN 3ML, classified under the federal contract description code 4566947222. The contract has an ultimate completion date of January 16, 2025, and is a Firm Fixed Price Delivery Order. AmerisourceBergen Drug Corp is the prime contractor,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Insulin Glargine-yfgn U100 Pen 3ML. The contract has a ceiling value of $2,626.00 and is a firm fixed price delivery order with a completion date of January 15, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves...
The U.S. government's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4563977468 - Insulin Glargine-YFGN U100 Pen 3ML to DLA Troop Support Medical. This $4,556.89 delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 awarded solely to AmerisourceBergen Drug Corp, which serves as the primary contract vehicle for the company to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,563,957,775 units of insulin glargine-yfgn U100 pen 3ml. The $1,977.12 contract has a performance period through March 14, 2024. This award is associated with a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 held by AmerisourceBergen Drug Corp as the prime contractor, which serves as the...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Insulin Glargine-yfgn U100 Pen 3ML, a critical medical commodity, over a period ending on January 21, 2025. The contract has a firm fixed price ceiling value of $9,744.82 and is designated as a delivery order, without any set-aside requirements. AmerisourceBergen holds a significant...
This is a $17,179.01 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 4565372242 Insulin Glargine-yfgn U100 Pen 3ML. The contract has an ultimate completion date of August 8, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support...
This is a firm fixed-price delivery order award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $42,359.34 contract is for the supply of Insulin Glargine-yfgn U100 Pen 3ML, a medication used to manage diabetes. The award has an ultimate completion date of January 31, 2025. This appears to be a task order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Insulin Glargine-yfgn U100 Pen 3ML. The contract has a Ceiling Value of $1,575.60 and runs through January 28, 2025. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Insulin Glargine-yfgn U100 Pen 3 mL. The contract is a delivery order with a firm fixed price of $1,977.12 and has an ultimate completion date of September 16, 2024. This contract is not set aside for any specific business category. AmerisourceBergen, through its Corporate Office division, will be responsible for delivering the insulin...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Insulin Glargine-yfgn U100 Pen 3ML, a type of insulin medication, with a ceiling value of $60,512.43 and a completion date of January 6, 2025. The contract is structured as a firm fixed-price delivery order and is not designated as a set-aside. AmerisourceBergen holds a larger...
  • SPE2DB20D3303
    Indefinite Delivery Contract
  • SPE2DB20D3303-SPE2DB24FA3HP
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Insulin Glargine-yfgn U100 Pen 3ML. The delivery order has a ceiling value of $4,685.76 and is a firm fixed-price contract with a completion date of September 23, 2024. The award is not associated with a set-aside program. AmerisourceBergen, through its extensive pharmaceutical supply chain network, will provide this critical insulin medication to support military treatment facilities and other federal healthcare providers. This contract represents one of many awards the company has received from various defense and civilian agencies, including the Department of Justice Federal Bureau of Investigation, to deliver a diverse range of pharmaceutical products and medical supplies to the U.S. government.

Generated 12/20/24, 9:34 AM